Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

LEVETIRACETAM IMPURITY D CRS (15 MG)

LEVETIRACETAM IMPURITY D CRS (15 MG)

103765-01-1

DISCOVER
ENROFLOXACIN CRS (5 MG)

ENROFLOXACIN CRS (5 MG)

93106-60-6

DISCOVER
TRIMEBUTINE FOR SYSTEM SUITABILITY CRS (1.02 MG)

TRIMEBUTINE FOR SYSTEM SUITABILITY CRS (1.02 MG)

34140-59-5

DISCOVER
LUFENURON FOR PEAK IDENTIFICATION CRS (0.4028 MG)

LUFENURON FOR PEAK IDENTIFICATION CRS (0.4028 MG)

103055-07-8

DISCOVER
FLUCYTOSINE FOR SYSTEM SUITABILITY CRS (0.3 MG)

FLUCYTOSINE FOR SYSTEM SUITABILITY CRS (0.3 MG)

2022-85-7

DISCOVER
ETACRYNIC ACID FOR SYSTEM SUITABILITY CRS (10 MG)

ETACRYNIC ACID FOR SYSTEM SUITABILITY CRS (10 MG)

58-54-8

DISCOVER
Aciclovir for system suitability CRS, 10mg

Aciclovir for system suitability CRS, 10mg

59277-89-3

DISCOVER
LUFENURON IMPURITY G CRS (15 MG)

LUFENURON IMPURITY G CRS (15 MG)

NA

DISCOVER
PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE CRS (5 MG)

PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE CRS (5 MG)

191217-81-9

DISCOVER
PRAMIPEXOLE IMPURITY D CRS (5MG)

PRAMIPEXOLE IMPURITY D CRS (5MG)

104632-27-1

DISCOVER
NICOTINIC ACID IMPURITY MIXTURE CRS (0.12 MG)

NICOTINIC ACID IMPURITY MIXTURE CRS (0.12 MG)

NA

DISCOVER
Aciclovir for peak identification 2 CRS, 0.004mg

Aciclovir for peak identification 2 CRS, 0.004mg

59277-89-3

DISCOVER